(PRWEB UK) 13 March 2014
Espicom Business Intelligence has just released the first issue of news service, Cardiometabolic Drug News. The lead story reports on the beginnings of Eisai’s patient study of weight loss medication Lorcaserin (Belviq) and what the outcome of the five year trial could mean for Eisai’s sales. Espicom notes that the weight loss drug, which has already launched in the US, has good market potential but still holds much risk, until the trial’s completion.
Espicom reports that the trial is to evaluate the effect of long-term treatment with lorcaserin HCI (Belviq) on the incidence of major adverse cardiovascular (CV) events and new-onset Type II diabetes in obese and overweight patients with CV disease or CV risk factors.
Espicom notes that Belviq is believed to decrease food consumption and promote satiety by selectively activating certain receptors in the brain, and is to be used along with a reduced calorie diet and increased physical activity. It is noted that the completion of the study will satisfy post-marketing requirement from the FDA to evaluate the long-term safety of lorcaserin. Espicom reports that the outcome for this trial is pivotal for Belviq; a negative result could mean the end of the drug, but a positive one should boost Eisai’s sales.
Espicom Business Intelligence was acquired by Business Monitor International in August 2012. Espicom is a leading provider of specialist pharmaceutical and medical device market information. Based in the UK and with 30 years of experience, the company provides a wide range of specialist, market and country reports along with subscription services. Espicom’s comprehensive Cardiometabolic Drug News covers major developments of global companies in the areas of Type II Diabetes, Obesity and Cardiovascular Disease.